TABLE 3.
Nonneoplastic pathology in Pold1+/+, Pold1+/L604G, and Pold1+/L604K micea
| Strain | No. of cases (incidence [%]) of:
|
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Chronic hepatitis | Cardiomyopathy | Heart arteriosclerosis | Heart karyomegaly | Glomerulonephropathy | Acidophilic macrophage pneumonia | Spleen arteriosclerosis | Artery inflammation | Total nonneoplastic and neoplastic disease burden | |
| Wild type | 44 (76) | 31 (56) | 31 (36) | 31 (65) | 33 (54) | 33 (17) | 36 (11) | 31 (9) | 47 (87) |
| +/L604G | 56 (77) | 42 (88) | 42 (31) | 42 (76) | 50 (62) | 47 (34) | 39 (13) | 42 (10) | 59 (88) |
| +/L604K | 54 (72) | 12 (83) | 12 (33) | 12 (75) | 34 (75) | 25 (36) | 45 (20) | 15 (27) | 64 (94) |
a
Shown are the percentages of mice with the indicated pathology, diagnosed at the end of life. These nonneoplastic lesions were the most frequently noted in the study and were graded on a 0-to-4 severity scale, where 0 is normal or no change, 1 is minimal, 2 is mild, 3 is moderate, and 4 is marked or severe. To assign a numerical representation of the amount of disease present at the end of life, we summed the neoplastic burden (Table 2) and nonneoplastic lesions determined to be contributing to morbidity or mortality (grade 3 or higher) to generate the total disease burden.